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The effect of Botulinum Toxin type A (BoNT/A) on pain and neurogenic vasodilatation induced by application to the human
skin of thermal stimuli and capsaicin was evaluated in a double blind study. A capsaicin cream (0.5 ml of a 0.075%) was applied
to the skin of both forearms of eighteen subjects randomly pretreated with either BoNT/A (Botox) or 0.9% saline (NS). Capsaicin
was applied to a skin area either inside (protocol A) or adjacent to the BoNT/A treated area (protocol B). Pre-treatment with
BoNT/A did not affect thermal-specific and thermal-pain thresholds (by quantitative sensory testing). However, capsaicin-induced
pain sensation (by a visual analogue scale), flare area (by acetate sheet) and changes in cutaneous blood flow (CBF, by laser Doppler
flowmetry) were reduced when capsaicin was administered inside (protocol A) the BoNT/A treated area. In Protocol B, capsaicin-
induced pain was unchanged, and capsaicin-induced flare/increase in CBF were reduced only in the area treated with BoNT/A, but
not in the BoNT/A untreated area. Results indicate that (i) BoNT/A reduces capsaicin-induced pain and neurogenic vasodilatation
without affecting the transmission of thermal and thermal-pain modalities; (ii) reduction in capsaicin-induced pain occurs only if
capsaicin is administered into the BoNT/A pretreated area; (iii) reduction in neurogenic vasodilatation by BoNT/A does not con-
tribute to its analgesic action. BoNT/A could be tested for the treatment of conditions characterised by neurogenic inflammation
and inflammatory pain.
 2006 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.
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Botulinum Toxin type A (BoNT/A) is currently used
for the treatment of focal muscle overactivity and spas-
ticity (Tsui et al., 1986) and certain autonomic disorders,
including hyperhidrosis and scialorrea (Bushara and
Park, 1994; Erbguth and Naumann, 1999). The benefi-
cial effect of BoNT/A is considered to result from the0304-3959/$32.00  2006 International Association for the Study of Pain. P
doi:10.1016/j.pain.2006.10.030
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237102.
E-mail address: vtugnoli@hotmail.com (V. Tugnoli).blockade of either neuromuscular or autonomic cholin-
ergic junctions. In the last few years, attention has been
paid to the use of BoNT/A for the treatment of different
pain conditions. Pain diseases alleviated by BoNT/A
encompass two main categories: those related to muscle
disorders, including dystonia (Greene et al., 1990), spas-
ticity (Wissel et al., 2000), myofascial pain (Cheshire
et al., 1994; Porta, 2000), chronic pelvic pain (Brisinda
et al., 2004), tension-type headache (Gobel et al.,
2001), temporomandibular dysfunction (Freund et al.,
2000), and those possibly related to neurovascular disor-
ders, including migraine headache (Silberstein, 2001;ublished by Elsevier B.V. All rights reserved.
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Additional pain disorders treated with BoNT/A are
facial chronic pain (Borodic et al., 2001; Borodic and
Acquadro, 2002; Saper, 2002), trigeminal neuralgia
(Allam et al., 2005) and pain related to spinal cord
pathology (Jabbari et al., 2003).
The precise mechanism of the analgesic effect of
BoNT/A is still poorly understood, and additional
actions to the sole cholinergic blockade and muscular
relaxation may contribute to this. Previous investigation
apparently excluded a direct peripheral antinociceptive
effect of BoNT/A in human skin (Blersch et al., 2002).
In particular, results obtained from the measurement
of thermal and electric pain thresholds, acute pain per-
ception, hyperalgesia and flare in response to capsaicin
application to the human skin seemed to rule out a direct
analgesic effect of BoNT/A (Voller et al., 2003). Howev-
er, findings obtained in facial pain (Borodic et al., 2001;
Borodic and Acquadro, 2002) and in a rat model of
inflammatory pain (Cui et al., 2002; Aoki, 2003; Cui
et al., 2004) and in humans by transcutaneous electrical
stimulation (Kramer et al., 2003) focused on the possibil-
ity that BoNT/A somehow limits the functioning of a
subset of capsaicin-sensitive and neuropeptide-contain-
ing primary sensory neurons (Durham et al., 2004).
The aim of the present study was to investigate the
effect of BoNT/A on pain and neurogenic vasodilatation
induced by application of thermal stimuli and capsaicin
to the human skin. We used capsaicin because this drug,
by a unique molecular mechanism, the stimulation of
the transient receptor potential vanilloid-1 (TRPV1)
(Caterina et al., 1997), causes both pain and neurogenic
inflammatory responses (Holzer, 1991; LaMotte et al.,
1992; Geppetti and Holzer, 1996; Serra et al., 1998).
The effect of subcutaneous administration of BoNT/A
on capsaicin-induced neurogenic vasodilatation and
pain was studied by the measurement of the flare area,
the cutaneous blood flow (CBF) by laser Doppler flow-
metry (LDF) (Baron et al., 1999; Schmelz et al., 2000)
and by a subjective visual analogue pain scale (VAS),
respectively. Thresholds for thermal and thermoalgesic
modalities were measured by using the quantitative sen-
sory testing (QST) (Verdugo and Ochoa, 1992; Yarnit-
sky et al., 1995). Results indicate that treatment with
BoNT/A attenuates both pain and neurogenic vasodila-
tation evoked by capsaicin application, without affecting
thermal-specific and thermal-pain thresholds.2. Materials and methods
2.1. Subjects and design
Eighteen healthy, drug-free volunteers (10 males, 8
females), aged 30–47, were recruited from our department
staff. All participants gave their informed consent, and the
study was approved by the local Ethics Committee. Subjectswere advised not to take any medication or analgesics 48 h
before pain assessments. Forearms of each participant were
randomly treated with BoNT/A or the equivalent volume of
sterile saline solution 0.9% (NS) in a double-blind fashion:
the subject and investigator were unaware of the side of the
active treatment. A second investigator was in charge of pre-
paring and administering the injections and of monitoring
the effect of BoNT/A on sweat production in the follow up
(Minor test). As application of capsaicin to the human skin
produces two associated phenomena, burning pain and a flare
reaction (e.g., Simone et al., 1989), two different protocols were
performed with the aim to discriminate the possible effect of
BoNT/A treatment on the flare response, pain or both. The
sole difference between the two protocols was the area of cap-
saicin administration. In protocol A, capsaicin cream was
applied inside the skin area pretreated with BoNT/A or NS,
while in protocol B capsaicin cream was applied to a skin area
adjacent, but not included in the area pretreated with BoNT/A
or NS. Measurements of CBF and flare were carried out
around the area of capsaicin administration that corresponded
to the treated skin (BoNT/A or NS) for protocol A, and both
the treated and untreated skin for protocol B (Fig. 1).
2.2. Procedures and measures
On day one the area to be treated with BoNT/A or NS was
assessed by calculating 5 cm from elbow crease, tracing a line
joining the ulnar and the radial forearm margins. A segment
of 4 cm was delineated with a pen in the central part of the line.
A line of 6 cm was drawn perpendicularly to the first one, thus
describing a rectangular area of approximately 24 cm2 . These
landmarks facilitated the recognition of the treated zone dur-
ing each experimental step. Because of the uneven distribution
of nociceptive fields in forearm skin, the physiological property
of summation to reach pain perception and the large shape of
flare produced by capsaicin administration (Serra et al., 1998),
a large cutaneous area was treated in order to involve a rele-
vant number of capsaicin-sensitive fibres. The entire area was
subdivided into smaller areas (1 cm2) for a total of 24 sub-
areas. Two units (0.02 ml) of BoNT/A (Botox-Allergan,
100 U diluted in 1 ml of NS) or an equivalent volume of NS
was injected subcutaneously into each 1 cm2 sub-area for a
total of 48 U (0.48 ml).
On day 28 (4 weeks later) the second investigator performed
a Minor starch iodine test by painting the skin with iodine
solution and then dusting it with starch powder, to detect
the area of anhydrosis produced by BoNT/A pre-treatment.
During the cycloergometer test used to produce sweating the
subject was blindfolded and therefore not able to see the col-
our resulting from the Minor test. Invariably in all subjects a
complete focal anhydrosis was present and, accordingly, suc-
cessive experimental steps were carried out. All procedures,
as listed below, were performed on both forearms.
2.3. Quantitative sensory testing
On day 29 quantitative sensory testing (QST) for thermal-
specific and thermal-pain modalities was carried out in the
rectangular areas treated with BoNT/A or NS of forearms in
all the 18 subjects to verify the direct effect on thermal and
thermal-pain sensory fibres. Heat (HS) and cold sensitive (CS)
Fig. 1. Schematic representation of protocol A (left) and protocol B (right). Areas of BoNT/A or vehicle (NS) administration (rectangular areas),
areas of capsaicin administration (dark grey), areas of flare (diagonally light grey) and sites of cutaneous blood flow (CBF) recording are indicated.
CBF was recorded inside the area treated with capsaicin (CBFc) and at 1 cm (CBF1, CBFp1, CBFd1) and at 2 cm (CBF2, CBFp2, CBFd2) from the
site of capsaicin application.
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detected by using a computer controlled thermode based on
Peltier system and a thermal sensory analyzer (TSA 2001,
Medoc Ltd., Ramat Yishai, Israel). The thermode contact area
of 3 · 3 cm was applied to the middle of the forearm pretreated
area. Temperatures ranged between 32–0 C for CS and CP,
and 32–50 C for HS and HP. The rate of temperature changes
was 0.5 C/s, and interstimulus interval was 30 s. For each
modality five successive stimuli were delivered and results were
averaged. The interval between different modalities was 30 s.
The method of limits was used to calculate each value following
a standard procedure (Verdugo and Ochoa, 1992; Gruener and
Dyck, 1994).
2.4. Capsaicin application and assessment of pain (VAS), flare
and CBF
On day 30, capsaicin cream (0.075%) was applied to all sub-
jects, on one arm at random. In protocol A (10 subjects), the
cream (0.5 ml) was applied to a skin area of 2 · 2 cm in the mid-
dle of BoNT or NS treated rectangular area. In protocol B (8
subjects), the cream (0.5 ml) was applied to a skin of 1 · 4 cm
external, but adjacent, to the upper side of the rectangular pre-
treated area (Fig. 1). On day 31 capsaicin creamwas also applied
to the second arm, following the same modalities of administra-
tion as the first ones according to the twoprotocols. Each subject
reported the pain induced by capsaicin applying a vertical sign
ona line of 10 cm, ranging from0 (nopain sensation) to 10 (max-
imal pain sensation) at 5 (VAS5), 10 (VAS10), 20 (VAS20), 30
(VAS30) and 45 (VAS45) min. After 45 min, when the maximum
flare was achieved, capsaicin was gently removed to allow a cor-
rect CBF detection. The reddened area after capsaicin adminis-tration was outlined on an acetate sheet and measured with a
digital planimeter. CBF was recorded by LDF (Perimed 5001,
Sweden). In protocol A, the first probe was positioned in the
middle of the capsaicin-treated area (CBFc) and the others at
1 cm (CBF1) and 2 cm (CBF2) from the external margins, along
the major axis of the rectangular area, always above the area
treated with capsaicin and inside the BoNT/A or NS treated
skin. In protocol B, probes were positioned as indicated above
with respect to capsaicin administration. However, probes were
applied both below and above the capsaicin-treated area, e.g.,
inside or outside the BoNT/A or NS-treated skin (see Fig. 1,
CBFd1, CBFd2, CBFp1, CBFp2, respectively). CBF was
recorded for 2 min in order to obtain a regular flow in each site.
The mean CBF was expressed in arbitrary units.
2.5. Statistical analysis
All data in the text and figures are means ± standard devia-
tion (SD). Comparisons of values obtained in BoNT/A and NS
pretreated area were performed by using the one-way repeated
measures analysis of variance (ANOVA). Correlation between
flare areas and VAS values was performed by the least squares
method. A p value <0.05 was considered statistically significant.3. Results
3.1. Thermal-specific and thermal-pain thresholds and
spontaneous pain
Four weeks after the injections of either BoNT/A or
NS, mean thermal and thermal-pain thresholds were
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arms were not statistically different from those obtained
in the NS pretreated arms (Fig. 2). Capsaicin applica-
tion caused a sensation of burning pain in both arms
of all the subjects. In protocol A the magnitude of the
capsaicin-evoked pain was significantly reduced in the
skin pretreated with BoNT/A in comparison to the skin
pretreated with NS (Fig. 3). In the BoNT/A treated arm
the VAS value was significantly reduced by 45% as com-
pared to the NS after 5 min (1.1 ± 0.3 vs. 2 ± 0.5;
p < 0.001. Means ± SD), by 17.8% after 10 min
(2.5 ± 0.4 vs. 3.1 ± 0.4; p < 0.05), by 40.3% after
20 min (4.1 ± 0.7 vs. 6.9 ± 0.8; p < 0.001), by 35.5%
after 30 min (5.4 ± 0.7 vs. 8.4 ± 0.8; p < 0.001), and by
35.7% after 45 min (5.5 ± 0.7 vs. 8.5 ± 0.9; p < 0.001).
In protocol B no significant difference was observed inQST
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Fig. 3. Capsaicin-induced pain expressed by VAS values (means ± SD), for p
right. Black labels represent the results in BoNT/A pretreated skin, white lab
values was observed at each time point in the BoNT/A compared with ve
significant difference was observed in protocol B.pain perception following capsaicin application between
the two sides pretreated with either BoNT/A or NS
(Fig. 3).
3.2. Flare area on acetate sheet
Application of capsaicin produced a reddening of the
skin exposed to the drug and the surrounding area. Con-
sistently, in all subjects, the flare area, calculated 45 min
after capsaicin administration, was significantly
decreased in the BoNT/A treated arms as compared to
the NS pretreated arm. The mean flare area was reduced
by 18.8% in protocol A. In protocol B a significant
reduction of 24.4% was seen in the partial area (PA) pre-
treated with BoNT/A (Table 1). A significant correla-
tion was detected between the amplitude of the30 40 50
ure (C˚)
nd heat pain (HP) thresholds values were detected in both BoNT/A
ll values are means ± SD of 18 subjects. No significant difference was
protocol B
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rotocol A (10 subjects) on the left and protocol B (eight subjects) on the
els the results in vehicle pretreated one. A significant reduction of VAS
hicle pretreated forearms in protocol A (*p < 0.05; ***p < 0.001). No
Table 1
Effect of BoNT/A on the flare response produced by capsaicin
application in the human skin
Protocol A Protocol B
TA PA
Area of flare (cm2)
BoNT/A 27.7 ± 3.3** 32.5 ± 3.9** 7.3 ± 1.2*
NS 34.0 ± 3.8 38.9 ± 4.0 9.7 ± 1.7
Decrement (%) BoNT/A vs NS 18.5% 16.5% 24.7%
Areas of reddened skin reported on acetate sheets show a significant
decrement in BoNT/A pretreated area compared with vehicle ones for
both protocol A and B. In protocol B two flare areas have been cal-
culated: total area (TA) and partial area (PA) referred to the only
spreading to pretreated skin. Values are means ± SD, **p < 0.001,
*p < 0.01 (BoNT vs NS).
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both for BoNT/A treated side (r = 0.78, p < 0.01) and
NS treated side (r = 0.70, p < 0.05) (Fig. 4).
3.3. Cutaneous blood flow
Capsaicin application was associated with a marked
increase in CBF as detected by the LDF technique. In
protocol A capsaicin-evoked increase in CBFc was
higher than the increase in CBF1, that, in turn, was
higher than the increase in CBF2. CBFc was similar in
both BoNT/A and NS treated arms. In contrast,
CBF1 was significantly reduced by 40.9% (p < 0.001)
in the side pretreated by BoNT/A as compared to the
NS treated side. Similarly, CBF2 was reduced by
48.2% (p < 0.001) in the side pretreated with BoNT/A.
In protocol B, capsaicin-evoked increase in CBFc was
not statistically different in both BoNT/A and NS treat-
ed arms, and was similar to that observed in protocol A.
When recordings were performed inside the treated
areas, CBF was reduced (CBFd1 by 41.6%, p < 0.01,protocol A
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Fig. 4. Correlation between flare area and pain (VAS) in BoNT (black) aand CBFd2 by 40.9%, p < 0.01) in BoNT/A pretreated
skin as compared to the NS pretreated side. In contrast,
if CBF was recorded in the skin area not pretreated with
BoNT/A or NS no significant difference in both CBFp1
and CBFp2 was observed (Fig. 5).
4. Discussion
The present study shows that treatment of the human
skin with BoNT/A, while did not modify thermal and
thermal-pain thresholds, reduced pain evoked by capsa-
icin application. Failure of BoNT/A to affect thermal or
thermal-pain thresholds is consistent with previous stud-
ies, where, thresholds to heat and cold pain, electrical
stimulation (Blersch et al., 2002), heat pain and current
pain threshold/tolerance (Voller et al., 2003) were not
changed in the skin pretreated with BoNT/A. Present
results are at variance with a previous study (Voller
et al., 2003) showing that capsaicin-induced pain and
flare were not affected by BoNT/A. One possible expla-
nation for the discrepancy is that in the study by Voller
et al. (2003) the skin area, where capsaicin, injected
intradermally, might have diffused, exceeding the small
skin area (2.25 cm2) treated with BoNT/A. Studies with
TRPV1 knockout mice can shed some light into the
apparent contradiction that BoNT/A reduced capsai-
cin-induced pain, but did not affect thermal and ther-
mal-pain thresholds. Genetic deletion of TRPV1 did
not affect responses to acute noxious thermal stimuli,
but completely impaired the mouse ability to develop
thermal hyperalgesia (Caterina et al., 2000; Davis
et al., 2000), thus, suggesting that acute thermal-pain
is independent from direct TRPV1 stimulation.
In the present study the inhibitory effect of BoNT/A
on capsaicin-induced pain was observed solely if capsa-
icin was administrated inside the skin area pretreated
with BoNT/A (protocol A), but not if it was appliedprotocol B
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Fig. 5. Cutaneous blood flow (CBF) detected by laser Doppler flowmeter (LDF) expressed in perfusion units (arbitrary units) in BoNT/A pretreated
(black columns) and vehicle pretreated (grey columns) forearms in protocol A (left) and protocol B (right). No significant difference was observed at
the site of capsaicin administration (CBFc) for both protocols and for CBF1p and CBF2p for protocol B. A significant reduction in CBF was
observed both for CBF1 and CBF2 (protocol A) and for CBF1d and CBF2d for protocol B in BoNT/A pretreated forearms. (**p < 0.01;
***p < 0.001).
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(protocol B). In contrast, the flare response/increase in
CBF produced by capsaicin was inhibited by BoNT/A
either if capsaicin was applied to the same area or in
an area adjacent to that treated with BoNT/A. Present
data confirm, in part, a previous study which shows that
pretreatment with BoNT/A reduced the flare response
by painful transcutaneous electrical stimulation (Kra-
mer et al., 2003). However, the reduction in vasodilata-
tion observed in BoNT/A treated side does not seem to
contribute significantly to capsaicin-induced pain.
Stimulation of sensory C and A-delta fibres by capsa-
icin is due to its unique ability to activate the TRPV1
(Caterina et al., 1997; Szallasi, 2002). This effect produc-
es the typical sensation of burning pain and a series of
neuropeptide-mediated, inflammatory responses that
includes arterial vasodilatation (Geppetti and Holzer,
1996). The present findings, showing that to limit capsa-
icin-induced pain BoNT/A must be applied to the same
skin area, suggest that BoNT/A interferes either directly
on capsaicin-induced TRPV1-activation or on the
neurophysiological events that follow this activation in
the nerve axon and its arborisation. However, a specific
mechanism through which BoNT/A affects TRPV1-
mediated nerve excitation has not been demonstrated
so far.
The hypothesis that BoNT/A alters central transmis-
sion has been proposed because the toxin reduced the
inflammatory pain phase in the formalin pain model in
rats by decreasing glutamate release (Aoki, 2002, 2003;
Cui et al., 2004). Furthermore, diminished activity of
nociceptive neurons after BoNT/A administration was
confirmed by the reduction in c-fos gene and Fos proteinexpression (Welch et al., 2000; Cui et al., 2002). Howev-
er, attempts to demonstrate a direct action of BoNT/A
in nociceptive neurons have not been consistently repro-
duced (Blersch et al., 2002). Recent evidence has shown
that BoNT/A blocks SNARE (soluble N-ethylmalei-
mide-sensitive factor attachment protein receptors)-de-
pendent TRPV1 exocytosis to the neuron surface
(Morenilla-Palao et al., 2004). Thus, it may be proposed
that reduction in TRPV1 translocation to the plasma
membrane is responsible for reduced pain and neuro-
genic vasodilatation by BoNT/A.
Capsaicin releases vasodilatatory neuropeptides by a
local efferent function (mediated by direct TRPV1 acti-
vation) or via an axon reflex arrangement (Maggi and
Meli, 1988; Amann and Maggi, 1991). In the present
study, CBF recorded at the site of capsaicin application
(CBFc) was not affected by BoNT/A treatment that,
however, inhibited CBF at sites distant from the area
of application of capsaicin (CBF1 and CBF2). Thus,
BoNT/A does not seem to affect neurogenic vasodilata-
tion produced by the direct effect of capsaicin on
TRPV1 (CBFc), but, rather, inhibits the increase in
CBF presumably mediated by axon reflexes (CBF1
and CBF2). It should be, however, noted that failure
of BoNT/A to inhibit the increase in blood flow at CBFc
could have been due to the remarkable and probably
saturated response at this site, compared to the moder-
ate or mild responses seen at distance from the area of
drug application. It is possible that all sensory nerve
fibres are recruited by capsaicin at the site of drug appli-
cation (CBFc), whereas at distance from its application
(CBF1 and CBF2) only those fibres invaded by axon
reflexes contribute to the vasodilatation. The dose of
82 V. Tugnoli et al. / Pain 130 (2007) 76–83BoNT/A may therefore be sufficient to block the vasodi-
latation outside the treatment area, presumably pro-
duced by activation of a lower number of fibres, but
not the maximum vasodilatation produced inside the
treatment area.
BoNT/A blocks Ca2+-dependent release of neuro-
transmitter in cholinergic synapses, by cleaving SNARE
proteins essential for exocytosis (Simpson, 1981). The
high specificity of BoNT/A for cholinergic nerves is
due to the high affinity of BoNT H-chain for membrane
receptors located on presynaptic cholinergic terminals
(Montecucco and Schiavo, 1994). Recently, indirect evi-
dence has suggested that BoNT/A inhibits transmitter
release from neuropeptide containing nerve terminals
(Welch et al., 2000; Ishikawa et al., 2001; Caputi,
2004; Durham et al., 2004). The ability of BoNT/A to
reduce norepinephrine release from sympathetic nerves
has also been reported (Morris et al., 2002). The sympa-
thetic system and in particular norepinephrine/a1-
adrenoceptors seem to play an important role in capsa-
icin-induced pain and local inflammatory responses in
the skin in animal models and in man (Drummond,
1995; Drummond, 1998; Lin et al., 2003; Ren et al.,
2005), while the sympathetic sudomotor activity seems
to have no effect on capsaicin ongoing pain and hyper-
algesia (Wasner et al., 2000). Thus, it is possible that
BoNT/A treatment reduces neurogenic vasodilatation
and pain by inhibiting the release of norepinephrine.
However, the contribution, if any, of BoNT/A in the
regulation of transmitter release from adrenergic or neu-
ropeptide containing nerve fibres has not been clarified
yet. In conclusion, although the mechanism(s) underly-
ing the inhibitory effects remains unknown, the proved
ability of BoNT/A to inhibit neurotransmitter exocyto-
sis and the different responses of capsaicin-induced pain
and flare in relation to BoNT/A treated area could sug-
gest that, in our study, BoNT/A could act at two differ-
ent levels of capsaicin model, and more precisely at the
direct nervous afferent branch that is related to capsai-
cin-induced pain, for example by blocking SNARE-de-
pendent TRPV1 exocytosis, and at the efferent branch
of the axonal reflexes by inhibiting neuropeptide release
and the neurogenic vasodilatation. The present findings
reinforce the hypothesis that BoNT/A represents an
interesting opportunity to treat pain conditions charac-
terised by neurogenic inflammation and inflammatory
pain.
Note: During the completion of the revised version of
the present study, Gazerani et al. (2006) reported that
intramuscular injection of BoNT/A into the forehead
of healthy volunteers reduced both pain and flare
induced by capsaicin. These data are in agreement with
our present findings. However, the original and novel
finding of the present study, that application outside
the BoNT/A-treated area reduced capsaicin-evoked
flare, but not pain, does not support the hypothesis(Gazerani et al., 2006) that inhibition of sensory neuro-
peptide release is the exclusive and main underlying
mechanism of the reduction by BoNT/A of capsaicin-
evoked pain.Acknowledgement
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